MedPath

Phase2 study of Nab-Paclitaxel in patients with unresectable or advanced squamous cell lung cancer

Not Applicable
Recruiting
Conditions
squamous cell lung cancer
Registration Number
JPRN-UMIN000014558
Lead Sponsor
Tottori University Faculty of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
27
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patient with need of procedure for pleural effusion 2) History of hypersensitivity against albumin preparation 3) Patient with need of drainage procedure for cardiac effusion 4) Patient with symptomatic brain metastasis 5) Patient with severe complications. 6) Patients with interstitial pneumonia or pulmonary fibrosis diagnosed by chest X-ray 7) Female Patient in or having a chance or planning of pregnancy or breast feeding, 8) Male patient in planning to impregnate 9) Patient with active multiple cancers. 10) Patients with history of drug hypersensitivity 11) Patinets with histoly of hypersensitivity against Txeane agents include paclitaxel and docetaxel 12) Case which was judged as impossible to perform by physician in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease Control Rate(DCR)
Secondary Outcome Measures
NameTimeMethod
Response Rate(RR), Overall Surivival(OS), Progress Free Survival(PFS), Safety
© Copyright 2025. All Rights Reserved by MedPath